The project aims to use circulating tumor DNA to monitor drug response and resistance in metastatic melanoma patients in order to guide treatment decisions.
The partners aim to optimize DNA nanoball technology, accelerate the use of CTC technology, and work on a diagnostic tool for use at the point of care.
Researchers showed, retrospectively, that using a cutoff of 16 circulating DNA mutations they could identify patients who were more likely to respond to immunotherapy.
The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.
The Belgian cancer center plans to evaluate Natera's ctDNA assay for evaluating response and detecting minimal residual disease in breast cancer patients.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
